The test is the first of several planned CLIA-waived assays from Cepheid, and the first point-of-care test on the market to differentiate flu from RSV.
The partners are broadening their collaboration to bring point-of-care TB diagnostics to all levels of the health system in low- and middle-income countries.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
At the AMP meeting this week, JHU's Sara Sukumar discussed efforts to adapt a cell-free methylated DNA assay for breast cancer to a Cepheid Xpert cartridge.
The GenomeWeb Index was up around 2 percent, but its performance was well behind the broader stock market.
The firm claimed delays in a planned sales force expansion were partly to blame for lower-than-expected revenues; it also announced the FDA clearance of an assay for Trichomonas vaginalis.
The investment bank issued its downgrade citing concerns about changes to Cepheid's sales force and a flattening of its MRSA assay sales.
The firm reported results today in line with preliminary results reported last week, and affirmed its updated full-year guidance.
With recent and impending launches of POC MDx platforms, some industry observers believe the technology could replace some POC immunoassays in a few years.
In addition to a steep slide in the company's share price, Raymond James lowered its rating for Cepheid's stock to Market Perform.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.